One aspect of the present invention is concerned with a method of treating or preventing pulmonary inflammation as a complication ensuing from physical trauma, bacteraemia or viral inflection, said method comprising enterally administering at least one or more glutathione promoters selected from: −0.3-20 g, preferably 0.5-5 g pyruvate equivalents; −0.1-5 g, preferably 0.2-2 g oxaloacetate equivalents; −0.01-1 g, preferably 0.02-0.5 g lipoic acid equivalents; and at least 20 g of digestible water soluble carbohydrates, in the form of an aqueous liquid composition containing at least 10 g/l of said digestible water soluble carbohydrates. Another aspect of the invention relates to an aqueous liquid composition suitable for enteral administration containing: 2 to 20 wt. % digestible dissolved carbohydrates; two or more glutathione promoters selected from: 0.5 to 50 g/l pyruvate equivalents; 0.05 to 20 g/l oxaloacetate equivalents; 0.05 to 5 g/l cystein equivalents; and at least 45 wt % water.